Search Results for: 43

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET-

ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the B. Riley Securities Oncology Conference being held  virtually on January 27-28, 2022. Steven Shallcross, Chief Executive Officer and Chief

Lead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trials Designed for systemic delivery, high selectivity, and enhanced tumor access VCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMA Synthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time ROCKVILLE, Md., Dec.